Association of serum uric acid with left ventricular ejection fraction

Abstract

Context: Cardiometabolic risk factors play crucial roles in left ventricular dysfunctions (left ventricular failure): a defining feature of heart failure (HF) with preserved ejection fractions (HFpEF). Among the many, serum uric acid (SUA) is a controversial risk factor that needs to be investigated globally. Aim: We aim to elucidate a correlation of SUA with ejection fraction percentage (EF%) in patients with chronic HF supporting the probable notion of hyperuricemia being a prognostic biomarker. Settings and Design: This retrospective, cohort study was performed on patients who visited from January 2022 to June 2022 in the Department of Cardiology at a tertiary care hospital in Northeastern India. Methods: A series of 81 selected patients with known congestive HF were documented with various baseline, clinical, and biochemical parameters. Patients were divided into three groups based on EF% and their relation with SUA, along with other parameters was analyzed. Statistical Analysis: Data were presented as mean ± standard deviation and frequencies for continuous variables and categorical variables, respectively. ANOVA one-way tests were conducted for continuous variables and Chi-square tests for categorical variables. P< 0.05 was considered as statistically significant. Results: A significant correlation was established between levels of SUA and EF (P = 0.021). Hence, hyperuricemia is directly related to an increased risk of lower EF. Conclusion: Even when asymptomatic, SUA can be used as a prognostic biomarker in the assessment of HF diseases.